Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Axis Modul
2026-05-07
Gramine-Induced Ferroptosis in Triple-Negative Breast Cancer: Mechanistic Insights and Research Implications
Study Background and Research Question
Triple-negative breast cancer (TNBC) represents one of the most challenging subtypes of breast cancer due to its lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. As a result, TNBC is refractory to most targeted therapies and is often associated with poor prognosis and high rates of relapse. The urgent need for effective therapeutic strategies has prompted exploration into natural compounds, especially those with multi-targeted activity and reduced systemic toxicity (paper). Gramine, an indole alkaloid, has previously demonstrated anti-inflammatory, antimicrobial, and anticancer properties, but its mechanism of action in TNBC remained unclear. This study set out to elucidate whether gramine could suppress TNBC via ferroptosis—a form of regulated cell death distinct from apoptosis or necrosis—and to clarify the molecular pathways involved.Key Innovation from the Reference Study
The central innovation of this research lies in uncovering a novel regulatory axis by which gramine induces ferroptosis in TNBC cells. Specifically, the study identifies that gramine targets CUL3, an E3 ubiquitin ligase, to modulate the stability of MTDH (metadherin). This interaction leads to the destabilization of ferroptosis-suppressing factors and ultimately triggers cell death selectively in TNBC cells (paper). By dissecting the CUL3–MTDH–ferroptosis pathway, the study not only clarifies the mechanism of gramine’s anticancer effect but also introduces a promising avenue for targeted intervention in aggressive breast cancers.Methods and Experimental Design Insights
The investigation employed a multi-tiered experimental approach:- Compound Screening: 27 indole alkaloids were initially screened using CCK-8 cytotoxicity assays to identify candidates with selective anti-TNBC activity.
- Target Validation: The direct binding of gramine to candidate proteins was validated using LIP-MS (limited proteolysis–mass spectrometry), molecular docking, CETSA (cellular thermal shift assays), and DARTS (drug affinity responsive target stability) assays.
- Pathway Analysis: Western blotting was used to quantify the expression of key ferroptosis regulators (MTDH, SLC3A2, GPX4) following gramine treatment.
- Ferroptosis Characterization: Measurements of cellular ROS, Fe2+, malondialdehyde (MDA), and GSH were performed, alongside examination of mitochondrial morphology—key hallmarks of ferroptosis.
- Mechanistic Confirmation: Ferroptosis rescue experiments (using inhibitors) and MTDH knockdown were deployed to confirm the dependence of gramine’s effects on the CUL3–MTDH axis.
- In Vivo Validation: Efficacy and toxicity were assessed in two mouse xenograft models (4T1 and MDA-MB-231), reflecting the translational relevance of the findings.
Protocol Parameters
- assay | CCK-8 cytotoxicity | 22–28 μM IC50 | Selective inhibition of TNBC cell growth by gramine | paper
- assay | Western blotting | quantitative protein detection | Expression of MTDH, SLC3A2, GPX4 | paper
- assay | Ferroptosis marker detection | ROS, Fe2+, MDA, GSH (concentration not specified) | Hallmark assessment of ferroptosis induction in mammalian cells | paper
- assay | Live/dead cell staining (Calcein AM/PI) | qualitative/quantitative | Differentiation of live and dead mammalian cells post-treatment | workflow_recommendation
Core Findings and Why They Matter
Gramine was found to selectively inhibit TNBC cell viability with IC50 values in the range of ~22–28 μM, while sparing non-malignant cells (paper). Proteomic and functional analyses demonstrated that gramine directly interacts with CUL3, decreasing its E3 ubiquitin ligase activity towards MTDH. Stabilization of MTDH, in turn, resulted in downregulation of key ferroptosis-inhibiting proteins (SLC3A2, GPX4) and promoted the accumulation of ROS, Fe2+, and MDA—consistent with ferroptosis induction. Rescue experiments using ferroptosis inhibitors and genetic knockdown of MTDH reversed these effects, confirming the mechanistic pathway. In vivo, gramine treatment significantly suppressed tumor growth in two TNBC xenograft models without inducing observable systemic toxicity, supporting its translational potential for cancer therapy (paper).Comparison with Existing Internal Articles
Several internal resources further contextualize the relevance of robust cell viability and ferroptosis detection assays in TNBC research:- Annexin-V-APC.com provides a mechanistic overview of gramine-induced ferroptosis, aligning with the present study’s findings by emphasizing the CUL3–MTDH axis as a regulatory hub.
- Hemagglutinin-Precursor-114-122-Amide-Influenza-A-Virus.com discusses the application of Calcein AM/PI Live-Dead Cell Staining Kit I for real-time assessment of ferroptosis in TNBC models, demonstrating the synergy between mechanistic studies and advanced viability detection workflows.
- Surface-Antigen.com and AmericaPeptides.com articles underscore the critical role of fluorescence-based live/dead cell assays in evaluating cytotoxicity and viability in mammalian cells, particularly for oncology research and drug screening.
Limitations and Transferability
While the study rigorously validated the CUL3–MTDH axis as a mediator of gramine-induced ferroptosis, several limitations should be acknowledged:- Specificity of gramine for CUL3 and MTDH requires further evaluation, especially in diverse TNBC molecular subtypes and in human tissue samples.
- The reliance on mouse xenograft models, while translational, does not fully recapitulate the complexity of human disease microenvironments.
- Long-term toxicity and pharmacokinetics of gramine were not comprehensively characterized.
- Transferability to other cancer types or non-TNBC subtypes remains to be investigated and should be approached cautiously (paper).